CPT® Code 0233T

Deleted

Advanced glycation endproducts (AGEs) are metabolic byproducts that result from the non-enzymatic glycation of proteins and amino acids. These compounds accumulate in the skin and various tissues of all individuals, but their accumulation is notably accelerated in patients with certain medical conditions. The presence of increased levels of AGEs is associated with biomarkers that indicate disease severity and can aid in risk prediction for various health issues. Conditions such as diabetes, renal failure, congestive heart disease, lupus erythematosus, and individuals who have undergone solid organ transplants are particularly relevant, as these patients may experience heightened levels of AGEs. Furthermore, individuals at risk for cardiovascular complications may also exhibit increased AGE accumulation. The measurement of AGEs is performed using non-invasive spectrographic autofluorescence readers, which detect the autofluorescent properties of AGEs when exposed to specific wavelengths of light. During the procedure, measurements are typically taken from the volar side of the lower arm or another site that is free from skin defects. The AGE reader utilizes an excitation light source that emits light within the range of 300 to 420 nm, and the emitted light from the skin is subsequently analyzed using a spectrometer. A skin/autofluorescence ratio is calculated based on these measurements, and the physician is responsible for interpreting the results and providing a comprehensive written report of the findings.